The national multi-center registered clinical trial of the Pulse Field Ablation Therapeutic Apparatus (PFA) for atrial fibrillation therapy under local anesthesia was officially launched in April this year. As of now, all enrolled subjects have been successfully completed. The completed clinical follow-up showed that the subjects' various indicators have recovered well, and the treatment effect is significant, with no complications such as pulmonary vein stenosis, phrenic nerve injury, or atrial esophageal fistula in any of the subjects. This brings new hope for the safe and effective treatment of atrial fibrillation patients! At the same time, this product has been approved to enter the NMPA's special review process for innovative medical devices this year, greatly accelerating the process of the first domestically approved innovative medical PFA product to enter the Chinese market!

At 1:30 pm, the Alpmed Nanoknife Tumor Summit Forum officially began. Professor Xiaoyueyong from the Chinese People's Liberation Army General Hospital, Professor Wang Zhongmin from the Affiliated Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Professor Wei Yingtian from the Chinese PLA General Hospital, and Professor Xue Zhihao from Tianjin Medical University shared their expert consensus on the ablation of different organ tumors by Nanoknife, as well as detailed parameter settings and needle placement methods based on classic cases. After the first half of the lecture sharing session, the pre-release ceremony of the new book "Nanoknife Tumor Ablation Therapy" was held at the venue. The book was edited by Professor Xiao Yueyong and Professor Wang Zhongmin, with the participation of relevant experts in the field of intervention, and was revised after seven years of clinical practice. The attending experts at the scene gave their blessings for the new book, believing that "Nanoknife Tumor Ablation Therapy" can provide guidance and help for more colleagues in the field of imaging intervention and surgery in carrying out Nanoknife ablation therapy after its release.

Professor Xiao Yueyong gives a lecture

During the conference, the National Expert Database for Nanoknife Tumor Ablation Therapy Society - "Navigator" Program was launched. This project plans to hire top experts in the field of intervention nationwide to help more doctors smoothly carry out clinical applications of Nanoknife therapy and bring new hope for advanced  malignant tumor patients. Professor Xiao Yueyong, Professor Wang Zhongmin, Professor Hu  Xiaokun, Professor Jiang  Tian’an, and Mr. Zhang Jianhao, Chairman of Alpmed,participated in the launch ceremony.Chairman Zhang Jianhao awarded appointment letters to the appointed experts on-site.

During the second half of the conference, Professor Niu Lizhi from Fuda Cancer Hospital shared his experience and insights on using NanoKnife for ablation therapy by delving into actual case examples and surgical procedures. Professor Hu Xiaokun from The Affiliated Hospital of Qingdao University also discussed the application of domestically-produced NanoKnife in liver cancer therapy. In addition, Professor Jiang Tian'an from The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) and Professor Guo Yanwei from the Fifth Affiliated Hospital of Zhengzhou University gave fantastic presentations respectively. The discussion segment had a strong response both online and offline.

Professor Hu Xiaokun gives a lecture

Professor Niu lizhi Yueyong gives a lecture